致力于药物研发关键试剂的生产

15801534258
info@nebulabio.cn
产品名称 NebuSelect™ Recombinant Biotinylated Human CLEC12A/MICL/CLL-1, Avi-hFc-tag
目录号 NBL-242803
别名 CLEC12A/MICL/CLL-1; MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2
外观 see COA
分子量
CAS N/A
溶解度 Water Soluble
存储条件 Short term 4℃; Long term -20℃.
保存时间 2 years
备注1 Q5QGZ9-2
备注2
目录号 规格 价格 库存状态  
NBL-242803-100ug 100ug Inquire Inquire
NBL-242803-1mg 1mg Inquire Inquire
NBL-242803-Customized Size N/A Inquire Inquire


Product Name:

NebuSelect™ Recombinant Biotinylated Human CLEC12A/MICL/CLL-1, Avi-hFc-tag


Catalog#:

NBL-242803


Description:

NebuSelect™ Recombinant Biotinylated Human CLEC12A/MICL/CLL-1, Avi-hFc-tag(Cat#NBL-242803) is expressed in HEK293 with hFc tag and Avi tag at the N-Terminus.It contains His65-Ala265.


Species:

Human


Expression System:

HEK293


Molecular Weight: 

The protein has a predicted MW of 51.7 kDa. Due to glycosylation, the protein migrates to 67-70 kDa based on Bis-Tris PAGE result.


Target Name:

CLEC12A/MICL/CLL-1; MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2


Target Information:

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.


Amino Acid Sequence: 


Purity:

>95%


Formulation:

see COA


Endotoxin:

<1EU/ug(LAL Method)


Storage: 

4°C for short term. 

-20°C for long term.


To get more information, please contact us freely.

相关产品